High-throughput screen for novel antimicrobials using a whole animal infection model.
暂无分享,去创建一个
Anne E Carpenter | Annie L. Conery | F. Ausubel | J. Larkins-Ford | Ralph Mazitschek | K. Lewis | Gang Wu | T. Moy | G. Casadei | Jonah Larkins-Ford
[1] D. Bumann. Has nature already identified all useful antibacterial targets? , 2008, Current opinion in microbiology.
[2] Martin Serrano,et al. Nucleic Acids Research Advance Access published October 18, 2007 ChemBank: a small-molecule screening and , 2007 .
[3] F. Ausubel,et al. Models of Caenorhabditis elegans infection by bacterial and fungal pathogens. , 2008, Methods in molecular biology.
[4] G. Marshall,et al. The biology and future prospects of antivirulence therapies , 2008, Nature Reviews Microbiology.
[5] Audrey White,et al. Automated, quantitative screening assay for antiangiogenic compounds using transgenic zebrafish. , 2007, Cancer research.
[6] L. Buck,et al. An antidepressant that extends lifespan in adult Caenorhabditis elegans , 2007, Nature.
[7] Jon Clardy,et al. Small-molecule Inhibitors of Pseudomonas aeruginosa Biofilm Development , 2012, The Meducator.
[8] Anne E Carpenter,et al. CellProfiler: image analysis software for identifying and quantifying cell phenotypes , 2006, Genome Biology.
[9] Frederick M Ausubel,et al. Identification of novel antimicrobials using a live-animal infection model , 2006, Proceedings of the National Academy of Sciences.
[10] Trevor C. Y. Kwok,et al. A small-molecule screen in C. elegans yields a new calcium channel antagonist , 2006, Nature.
[11] Theresa Stiernagle. Maintenance of C. elegans. , 2006, WormBook : the online review of C. elegans biology.
[12] A. Marra. Targeting Virulence for Antibacterial Chemotherapy , 2006 .
[13] A. Marra. Targeting virulence for antibacterial chemotherapy: identifying and characterising virulence factors for lead discovery. , 2006, Drugs in R&D.
[14] S. Walker,et al. Discovery of O-GlcNAc transferase inhibitors. , 2005, Journal of the American Chemical Society.
[15] L. Silver. A retrospective on the failures and successes of antibacterial drug discovery. , 2005, IDrugs : the investigational drugs journal.
[16] M. Schmid. Seeing is believing: the impact of structural genomics on antimicrobial drug discovery , 2004, Nature Reviews Microbiology.
[17] A. Boggs,et al. Antibacterial drug discovery: is small pharma the solution? , 2004, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[18] S. Projan,et al. Antibacterial drug discovery: is it all downhill from here? , 2004, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[19] C. Walsh. Opinion — anti-infectives: Where will new antibiotics come from? , 2003, Nature Reviews Microbiology.
[20] Anders Olsen,et al. An automated high-throughput assay for survival of the nematode Caenorhabditis elegans. , 2003, Free Radical Biology & Medicine.
[21] Cori Bargmann,et al. SEK‐1 MAPKK mediates Ca2+ signaling to determine neuronal asymmetric development in Caenorhabditis elegans , 2002, EMBO reports.
[22] Thomas D. Y. Chung,et al. A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays , 1999, Journal of biomolecular screening.
[23] F. Ausubel,et al. Killing of Caenorhabditis elegans by Pseudomonas aeruginosa used to model mammalian bacterial pathogenesis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[24] S. Strome,et al. Characterization of a germ-line proliferation mutation in C. elegans. , 1992, Development.